Incomplete submissions will not be fully refunded, says FDA
This article was originally published in Clinica
Executive Summary
The latest guidance from the FDA on medical device user fees and refunds notes that companies face steep financial penalties for submitting premarket approval applications (PMA) that are not sufficiently complete. If the application is so incomplete that the FDA refuses to file it, the agency said it will refund only 75% of the fee paid. And the money cannot be recouped. When the PMA is submitted again, the full fee will be levied, the FDA said.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.